RxDoctor Payments Data

Donald Fornace, DO

Cardiovascular Disease · Ormond Beach, FLNPI 1669494480

Payments from drug & device makers

$1,790in general payments, 2019–2025

Across 89 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$468
  • E.r. Squibb & Sons, L.L.C.$384
  • Lilly USA, LLC$242
  • Novo Nordisk$224
  • Novartis$201
  • Boston Scientific$136
  • plus $135 from 5 others

What the payments were for

  • Food & beverage$1,790100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen26$468
E.r. Squibb & Sons, L.L.C.23$384
Lilly USA, LLC9$242
Novo Nordisk13$224
Novartis8$201
Boston Scientific2$136
Abbott2$48
Pfizer2$34
Esperion Therapeutics, Inc.2$24
Bardy Diagnostics, Inc.1$15
Atricure, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,790 in reported general payments places this provider in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$336,885
Medicare patients
488
Services billed
3,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban409$439,780
OzempicSemaglutide242$271,420
Repatha SureclickEvolocumab414$253,789
MounjaroTirzepatide179$229,296
EntrestoSacubitril/Valsartan61$70,316
Praluent PenAlirocumab100$58,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter60$47,543
XareltoRivaroxaban28$36,046
JardianceEmpagliflozin28$30,696
Rosuvastatin Calcium596$11,051
Ezetimibe202$5,283
Atorvastatin Calcium346$4,376
Diltiazem 24hr Er (Cd)Diltiazem Hcl159$4,336
Bumetanide81$2,583
Spironolactone211$2,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$439,780409 claims
Novo NordiskOzempic$224$271,420242 claims
Lilly USA, LLCMounjaro$242$229,296179 claims
NovartisEntresto$201$70,31661 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →